Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro

Leukemia Research

Volumn 34, Issue 7, 2010, Pages 925-931

  Biswas, Sabyasachi ^a   Zhao, Xiaobin ^a   Mone, Andrew P ^a   Mo, Xiaokui ^a   Vargo, Melissa ^a   Jarjoura, David ^a   Byrd, John C ^a,b   Muthusamy, Natarajan ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Arsenic trioxide; Ascorbic acid; CLL

Indexed keywords

AMINOTRIAZOLE; APOLIZUMAB; ARSENIC TRIOXIDE; ASCORBIC ACID; BUTHIONINE SULFOXIMINE; CATALASE; GLUTATHIONE; REACTIVE OXYGEN METABOLITE;

ARTICLE; B CELL LEUKEMIA; CELL DEATH; CELL MEDIATED CYTOTOXICITY; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CONCENTRATION RESPONSE; CYTOTOXICITY TEST; DRUG EFFICACY; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; LEUKEMIA CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL;

AMINO ACID CHLOROMETHYL KETONES; AMITROLE; ANTIBODIES, MONOCLONAL; ARSENICALS; ASCORBIC ACID; B-LYMPHOCYTES; BUTHIONINE SULFOXIMINE; CATALASE; CELL LINE, TUMOR; CYSTEINE PROTEASES; CYSTEINE PROTEINASE INHIBITORS; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; ENZYME ACTIVATION; GLUTATHIONE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; NEOPLASM PROTEINS; OXIDANTS; OXIDATIVE STRESS; OXIDES; REACTIVE OXYGEN SPECIES;

EID: 77952952716     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.01.020     Document Type: Article

References (38)

1. 2 toxicity than T lymphocytes. J Immunol 1984, 132:2543-2546.
2. Oltra A.M., Carbonell F., Tormos C., Iradi A., Saez G.T. Antioxidant enzyme activities and the production of MDA and 8-oxo-dG in chronic lymphocytic leukemia. Free Radic Biol Med 2001, 30:1286-1292.
3. Farber C.M., Kanganis D.N., Liebes L.F., Silber R. Antioxidant enzymes in lymphocytes from normal subjects and patients with chronic lymphocytic leukaemia: increased glutathione peroxidase activity in CLL B lymphocytes. Br J Haematol 1989, 72:32-35.
4. Moran E.C., Kamiguti A.S., Cawley J.C., Pettitt A.R. Cytoprotective antioxidant activity of serum albumin and autocrine catalase in chronic lymphocytic leukaemia. Br J Haematol 2002, 116:316-328.
5. Ivanov V.N., Hei T.K. Arsenite sensitizes human melanomas to apoptosis via tumor necrosis factor alpha-mediated pathway. J Biol Chem 2004, 279:22747-22758.
6. Zhu J., Okumura H., Ohtake S., Nakamura S., Nakao S. The molecular mechanism of arsenic trioxide-induced apoptosis and oncosis in leukemia/lymphoma cell lines. Acta Haematol 2003, 110:1-10.
7. 2/caspase-8 pathway engaging the mitochondrial pathway in myeloma cells with mutant p53. Cell Cycle 2003, 2:358-368.
8. Cai X., Yu Y., Huang Y., Zhang L., Jia P.M., Zhao Q., et al. Arsenic trioxide-induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells. Leukemia 2003, 17:1333-1337.
9. Zhu J., Okumura H., Ohtake S., Nakamura S., Nakao S. Arsenic trioxide induces apoptosis in leukemia/lymphoma cell lines via the CD95/CD95L system. Oncol Rep 2003, 10:705-709.
10. 3) on leukemic cells from patients with non-M3 acute myelogenous leukemia: studies of cytotoxicity, apoptosis and the pattern of resistance. Eur J Haematol 2001, 66:357-364.
11. 3) in the treatment of patients with acute promyelocytic leukemia: the M.D. Anderson experience. Cancer 2003, 97:2218-2224.
12. Tsimberidou A.M., Estey E., Whitman G.J., Dryden M.J., Ratnam S., Pierce S., et al. Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies. Leuk Res 2004, 28:991-994.
13. Douer D., Hu W., Giralt S., Lill M., DiPersio J. Arsenic trioxide (trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation. Oncologist 2003, 8:132-140.
14. Zhu J., Chen Z., Lallemand-Breitenbach V., de The H. How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer 2002, 2:705-713.
15. Mayorga J., Richardson-Hardin C., Dicke K.A. Arsenic trioxide as effective therapy for relapsed acute promyelocytic leukemia. Clin J Oncol Nurs 2002, 6:341-346.
16. Bachleitner-Hofmann T., Kees M., Gisslinger H. Arsenic trioxide: acute promyelocytic leukemia and beyond. Leuk Lymphoma 2002, 43:1535-1540.
17. Shi H., Shi X., Liu K.J. Oxidative mechanism of arsenic toxicity and carcinogenesis. Mol Cell Biochem 2004, 255:67-78.
18. Chou W.C., Jie C., Kenedy A.A., Jones R.J., Trush M.A., Dang C.V. Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proc Natl Acad Sci U S A 2004, 101:4578-4583.
19. Hughes M.F. Arsenic toxicity and potential mechanisms of action. Toxicol Lett 2002, 133:1-16.
20. Hirano S., Kobayashi Y., Cui X., Kanno S., Hayakawa T., Shraim A. The accumulation and toxicity of methylated arsenicals in endothelial cells: important roles of thiol compounds. Toxicol Appl Pharmacol 2004, 198:458-467.
21. Bachleitner-Hofmann T., Gisslinger B., Grumbeck E., Gisslinger H. Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia?. Br J Haematol 2001, 112:783-786.
22. Grad J.M., Bahlis N.J., Reis I., Oshiro M.M., Dalton W.S., Boise L.H. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 2001, 98:805-813.
23. Cheson B.D., Bennett J.M., Rai K.R., Grever M.R., Kay N.E., Schiffer C.A., Oken M.M., Keating M.J., Boldt D.H., Kempin S.J., et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am J Hematol 1988, 29(3):152-163.
24. Mone A.P., Huang P., Pelicano H., Cheney C.M., Green J.M., Tso J.Y., et al. Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells. Blood 2004, 103:1846-1854.
25. Miller W.H., Schipper H.M., Lee J.S., Singer J., Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002, 62:3893-3903.
26. Nakagawa Y., Akao Y., Morikawa H., Hirata I., Katsu K., Naoe T., et al. Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines. Life Sci 2002, 70:2253-2269.
27. Woo S.H., Park I.C., Park M.J., Lee H.C., Lee S.J., Chun Y.J., et al. Arsenic trioxide induces apoptosis through a reactive oxygen species-dependent pathway and loss of mitochondrial membrane potential in HeLa cells. Int J Oncol 2002, 21:57-63.
28. Davison K., Cote S., Mader S., Miller W.H. Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia 2003, 17:931-940.
29. Shimizu M., Hochadel J.F., Fulmer B.A., Waalkes M.P. Effect of glutathione depletion and metallothionein gene expression on arsenic-induced cytotoxicity and c-myc expression in vitro. Toxicol Sci 1998, 45:204-211.
30. Silber R., Farber C.M., Papadopoulos E., Nevrla D., Liebes L., Bruck M., et al. Glutathione depletion in chronic lymphocytic leukemia B lymphocytes. Blood 1992, 80:2038-2043.
31. Bakan N., Taysi S., Yilmaz O., Bakan E., Kuskay S., Uzun N., et al. Glutathione peroxidase, glutathione reductase, Cu-Zn superoxide dismutase activities, glutathione, nitric oxide, and malondialdehyde concentrations in serum of patients with chronic lymphocytic leukemia. Clin Chim Acta 2003, 338:143-149.
32. Ferraris A.M., Rolfo M., Mangerini R., Gaetani G.F. Increased glutathione in chronic lymphocytic leukemia lymphocytes. Am J Hematol 1994, 47:237-238.
33. Mavromatis B., Cheson B.D. Monoclonal antibody therapy of chronic lymphocytic leukemia. J Clin Oncol 2003, 21:1874-1881.
34. O'Brien S.M., Kantarjian H., Thomas D.A., Giles F.J., Freireich E.J., Cortes J., et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001, 19:2165-2170.
35. Byrd J.C., Murphy T., Howard R.S., Lucas M.S., Goodrich A., Park K., et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001, 19:2153-2164.
36. Stockmeyer B., Schiller M., Repp R., Lorenz H.M., Kalden J.R., Gramatzki M., et al. Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor-primed effector cells and Hu1D10-a humanized human leucocyte antigen DR antibody. Br J Haematol 2002, 118:959-967.
37. Karasavvas N., Cárcamo J.M., Stratis G., Golde D.W. Vitamin C protects HL60 and U266 cells from arsenic toxicity. Blood 2005, 105(May 10):4004-4012.
38. Merkel O., Heyder C., Asslaber D., Hamacher F., Tinhofer I., Holler C., et al. Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13. J Mol Med 2008 May, 86(5):541-552.